SCHEMBL28857129

SCHEMBL28857129

CC(C)(C)CCO[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.47
WDR77 Q9BQA1 2/20 0.47
HPGD P15428 1/20 0.43
PIK3CD O00329 3/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR119 Q8TDV5 4/20 0.42
RECQL P46063 1/20 0.42
EPHX1 P07099 1/20 0.42
USP30 Q70CQ3 1/20 0.41
NR1H2 P55055 1/20 0.41
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28857131 1.00 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL23364705 0.92 MEN1 (0.50) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL15600251 0.87 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL16419551 0.87 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL16415212 0.87 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL16520107 0.87 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL8295157 0.87 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL2145886 0.86 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL31421263 0.86 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1
SCHEMBL31421243 0.86 PRMT5 (0.47) PRMT5WDR77HPGDPIK3CDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed